Clinical Trial Detail

NCT ID NCT02326844
Title BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

ovarian cancer

Therapies

Talazoparib

Age Groups: adult

Additional content available in CKB BOOST